Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ashley

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Cancers|September 28, 2023
Repurposing Clemastine to Target Glioblastoma Cell StemnessMichael A Sun, Rui Yang, Heng Liu, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2023
The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical PracticeAlex Broom, Leah Williams Veazey, Katherine Kenny, et al.
The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.
Neuro-Oncology|December 1, 2021
Establishment of patient-derived organoid models of lower-grade gliomaKalil G Abdullah, Cylaina E Bird, Joseph D Buehler, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.
Science Translational Medicine|February 8, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma modelsScott Parker, Charlotte McDowall, Luis Sanchez-Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2024
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201Jordan R Hansford, Gauthier Bouche, Vijay Ramaswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Cancers|September 28, 2023
Repurposing Clemastine to Target Glioblastoma Cell StemnessMichael A Sun, Rui Yang, Heng Liu, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2023
The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical PracticeAlex Broom, Leah Williams Veazey, Katherine Kenny, et al.
The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.
Neuro-Oncology|December 1, 2021
Establishment of patient-derived organoid models of lower-grade gliomaKalil G Abdullah, Cylaina E Bird, Joseph D Buehler, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Systematic review of combinations of targeted or immunotherapy in advanced solid tumorsAaron C Tan, Stephen J Bagley, Patrick Y Wen, et al.
Science Translational Medicine|February 8, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma modelsScott Parker, Charlotte McDowall, Luis Sanchez-Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2024
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201Jordan R Hansford, Gauthier Bouche, Vijay Ramaswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
Pageof 13